Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TSPO

TSPO

Basics

Aliases:
This biomarker is also known as:
  • IBP,
  • BPBS,
  • translocator protein (18kDa),
  • Peripheral-type benzodiazepine receptor,
  • mitochondrial benzodiazepine receptor,
  • pk18,
  • benzodiazepine peripheral binding site,
  • benzodiazapine receptor (peripheral),
  • BZRP,
  • Mitochondrial benzodiazepine receptor,
  • DBI,
  • peripheral-type benzodiazepine receptor,
  • MBR,
  • translocator protein,
  • PBRS,
  • mDRC,
  • PBS,
  • PTBR,
  • PBR,
  • PKBS,

View in BioMuta

Description…

TSPO is a conserved protein found at the outer mitochondrial membrane. TSPO interacts with some benzodiazepines and isoquinoline carboxamides and has different affinities than its endogenous counterpart. TSPO is also involved in the transport of porphyrins and heme.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: TSPO

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

The TSPO gene is known to be over-expressed in highly aggressive tumors, especially those of the breast. Increasing levels of the TSPO protein are correlated with more advanced stages of breast cancer. Higher TSPO levels are found in estrogen receptor (ER)-negative breast tumors, compared with ER-positive tumors.

Performance Comment

TSPO was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.